WO1985004579A1 - New phenoxypropanolamine salts and pharmaceutical preparations thereof - Google Patents

New phenoxypropanolamine salts and pharmaceutical preparations thereof Download PDF

Info

Publication number
WO1985004579A1
WO1985004579A1 PCT/SE1985/000159 SE8500159W WO8504579A1 WO 1985004579 A1 WO1985004579 A1 WO 1985004579A1 SE 8500159 W SE8500159 W SE 8500159W WO 8504579 A1 WO8504579 A1 WO 8504579A1
Authority
WO
WIPO (PCT)
Prior art keywords
alprenolol
salts
tablets
salt
benzoate
Prior art date
Application number
PCT/SE1985/000159
Other languages
English (en)
French (fr)
Inventor
John Albert SJÖGREN
Original Assignee
Aktiebolaget Hässle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aktiebolaget Hässle filed Critical Aktiebolaget Hässle
Publication of WO1985004579A1 publication Critical patent/WO1985004579A1/en
Priority to DK553285A priority Critical patent/DK553285A/da
Priority to KR1019850700365A priority patent/KR860700008A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Definitions

  • the present invention is related to new salts of the compound alprenolol which is a therapeutically active compound used in treatment of cardiac disorders such as hypertension, angina pectoris and arrhythmias.
  • the pharmacological effect of alprenolol is exerted through blockade of beta receptors in the autonomic nerve system.
  • alprenolol is used as the hydrochloride.
  • alprenolol hydrochloride has a strong local irritating effect. A number of ulcerations in the oesophagus of patients have been reported.
  • the object of the invention is to provide alprenolol in a form that avoids the side effects mentioned while maintaining a high absorption of the drug from the gastrointestinal system.
  • Alprenolol having the systematic name 1-(2-allylphenoxy)-3-isopropyl- amino-2-propanol, is described in SE-C-2 4 378, GB-C-1 140 508, DE-C-1 294955 and FR-C-1 479614.
  • salts were proposed the hydro ⁇ chloride, lactate, sulfate and sulfamate.
  • phenoxypropanolamines salts of numerous acids have been proposed in generic and specific terms.
  • the present invention provides as new salts the salts of alprenolol with benzoic acid or maleic acid. These salts ' are found to be very well tolerated and they are not causing damages on the oesophagus.
  • the absorption of the new salts is about as high as for the hydrochloride.
  • Preferred salts are alprenolol benzoate and alprenolol hydrogen aleate. Most preferred is alprenolol benzoate,
  • Oral pharmaceutical preparations of the new alprenolol salts are found to provide the greatest advantages over previously known oral alprenolol preparations, and thus such oral preparations constitute a preferred embodiment of the invention. However, the new salts may advantageously be used also in rectal pharmaceutical preparations.
  • the new salts of the invention may be formulated into pharmaceutical preparations in a manner known per se. They are suitable also for forming slow-release preparations, as they have a high content of the active compound alprenolol. It is thus possible to produce both products which are rapidly absorbed and products with a prolonged duration.
  • the alprenolol salt may be mixed with suitable excipients such as lactose, saccharose, sorbitol, mannitol, starch such as potato starch, corn starch, amylopectin, cellulose derivatives or gelatine, as well as with a lubricating a.gent such as magnesium stearate, calcium stearate, polyethyleneglycol , or the like, and be pressed into tablets.
  • suitable excipients such as lactose, saccharose, sorbitol, mannitol, starch such as potato starch, corn starch, amylopectin, cellulose derivatives or gelatine
  • a lubricating a.gent such as magnesium stearate, calcium stearate, polyethyleneglycol , or the like
  • the above prepared ' core may be coated with a concentrated solution of sugar, which solution may contain e.g. gum arabic, gelatine, talc, titandioxide or
  • soft gelatine capsules pearl-shaped, closed capsules
  • soft gelatine capsules which consist of gelatine and e.g. glycerine
  • the alprenolol salt is mixed with a vegetable oil.
  • Hard gelatine capsules may contain the active compound in combination with suitable excipients . such as lactose, saccharose, sorbitol, mannitol, starch (such as e.g. potato starch, corn starch or amylopectin), cellulose derivatives or magnesium stearate.
  • Dosage units for rectal administration may be prepared in the form of suppositories, which contain the active substance in a mixture with a neutral fat base, or they may be prepared in the form of gelatine-rectal capsules which contain the active substance in- a mixtur with a vegetable oil or paraffin oil.
  • alprenolol salts of the invention may be administered in equal molar amounts as recommended for alprenolol hydrochloride.
  • suitable daily dosages of the new salts would be from 0.1 to 1.5 g.
  • Dosage units may suitably contain amounts corresponding to 50 to 200 mg alprenolol hydrochloride.
  • the salts of the invention may be prepared in a manner known per se by reacting alprenolol base with maleic acid and benzoic acid, respect- ively.
  • Alprenolol hydrogenmaleate (128 g, corresponding to 100 g of alprenolol hydrochloride) was mixed with anhydrous lactose (136 g), microcrystall ⁇ ine cellulose (90.7 g) and magnesium stearate (3.3 g). The mixture was compressed into tablets with 10 mm diameter weighing 358 mg. The tablets disintegrated in 37°C water in 3 min. (test according to USP XX)
  • Alprenolol benzoate (130 g, corresponding to 100 g alprenolol hydro ⁇ chloride) was mixed with anhydrous lactose, microcrystalline cellulose and magnesium stearate according to Example 3. Tablet weight 360 mg. Disintegration time according to USP XX 3.5 min.
  • Tablets were prepared in a manner analogous to Example 3 of a mixture of alprenolol benzoate (260 g), anhydrous lactose (142 g), micro ⁇ crystalline cellulose (181 g), crosslinked polyvinylpyrrolidone (29 g) and magnesium stearate (6 g).
  • the tablet weight was 309 mg and the time of disintegration 20 s.
  • Slow release tablets were prepared by mixing alprenolol benzoate (260 g) with magnesium stearate (26 g). The mixture was moistened with a solution of 12.6 g ethyl cel ulose 10 cps in 71 g of ethanol 95%. The moist mass was dried and milled through a 1.0 mm sieve. Anhydrous lactose (115 g), microcrystalline cellulose (90 g) and magnesium stearate (4.9 g) were added. Tablets weighing 510 mg were made with 12 mm punches. The tablets disintegrated very slowly. The dissolution properties in artificial gastric juice were compared with commercial
  • Alprenolol hydrogenmaleate 64 g was granulated with ethanol (17 g). After drying the granules were sieved through a 0.7 mm sieve and mixed with anhydrous lactose (136 g), microcrystalline cellulose (91 g), cross!inked polyvinylpyrrolidone (14.5 g) and magnesium stearate (3 g). The mixture was compressed into tablets with 10 mm diameter weighing 308 mg. The disintegration time was about 10 s and the dissolution in artificial gastric juice was complete in 10 min.
  • a slow release preparation based on a large number of individually coated small pellets was prepared in the following manner.
  • Alprenolol benzoate (74 g), microcrystalline cellulose (16 g), di-sodium hydrophosphate (10 g) were mixed in an intensive mixer. The mixture was moistened with about 35 g of water and was worked until round granules were formed. These were dried and granules greater than 1.0 mm and smaller than 0.5 mm were sieved off. The granules were coated in a fluid-bed coating equipment with a solution consisting of 10 g ethyl cellulose, 2.5 g hydroxypropyl cellulose and 2.5 kg ethanol. After drying the granules were filled into hard gelatine capsules in an amount corresponding to 200 mg of alprenolol hydrochlori.de.
  • the capsules thus prepared disintegrate after ingestion and then releas the dosage as a large number of small granules each contained within a coating which causes slow release of the drug. By these means further safety against local damage in the digestive channel is achieved.
  • Tablets prepared according to Examples 3 and 4 were compared on oesophagus-irritating effect with tablets containing 100 mg alprenolol hydrochloride (Aptin , AB-Hassle) and tablets containing di-alprenolol fumarate in an amount corresponding to 100 g of the hydrochloride, said tablets being prepared in analogy with Example 3.
  • the test was carried out in the anaesthetized pig by lowering the tablets into the oesophagus and fixing with a silk thread according to Olofsson et al., Acta Pharmacol, et Toxicol. 53, 385-391 (1983).
  • tablets containing the alprenolol salts of maleic acid and benzoic acid produced substantially less harmful effects than did the marketed alprenolol hydrochloride product.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
PCT/SE1985/000159 1984-04-05 1985-04-03 New phenoxypropanolamine salts and pharmaceutical preparations thereof WO1985004579A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DK553285A DK553285A (da) 1984-04-05 1985-11-29 Fenoxypropanolaminsalte og farmaceutiske praeparater deraf
KR1019850700365A KR860700008A (ko) 1984-04-05 1985-12-04 신규 페녹 시프로판올 아민 염 및 그의 약제

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8401907A SE8401907L (sv) 1984-04-05 1984-04-05 Nya fenoxipropanolaminsalter och farmaceutiska beredningar derav
SE8401907-4 1984-04-05

Publications (1)

Publication Number Publication Date
WO1985004579A1 true WO1985004579A1 (en) 1985-10-24

Family

ID=20355474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1985/000159 WO1985004579A1 (en) 1984-04-05 1985-04-03 New phenoxypropanolamine salts and pharmaceutical preparations thereof

Country Status (19)

Country Link
EP (1) EP0209520A1 (enrdf_load_stackoverflow)
JP (1) JPS61501779A (enrdf_load_stackoverflow)
KR (1) KR860700008A (enrdf_load_stackoverflow)
AP (1) AP8500009A0 (enrdf_load_stackoverflow)
AU (1) AU4231185A (enrdf_load_stackoverflow)
DD (1) DD232488A5 (enrdf_load_stackoverflow)
ES (1) ES8609210A1 (enrdf_load_stackoverflow)
GB (1) GB2153828B (enrdf_load_stackoverflow)
GR (1) GR850840B (enrdf_load_stackoverflow)
HK (1) HK55586A (enrdf_load_stackoverflow)
IL (1) IL74611A0 (enrdf_load_stackoverflow)
MA (1) MA20396A1 (enrdf_load_stackoverflow)
MY (1) MY8600650A (enrdf_load_stackoverflow)
NO (1) NO854518L (enrdf_load_stackoverflow)
PL (1) PL252660A1 (enrdf_load_stackoverflow)
PT (1) PT80232B (enrdf_load_stackoverflow)
SE (1) SE8401907L (enrdf_load_stackoverflow)
WO (1) WO1985004579A1 (enrdf_load_stackoverflow)
ZA (1) ZA851934B (enrdf_load_stackoverflow)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE322506B (enrdf_load_stackoverflow) * 1964-09-10 1970-04-13 Ciba Geigy
DK117963B (da) * 1963-07-19 1970-06-22 Ici Ltd Fremgangsmåde til fremstilling af aryloxyalkanolaminderivater eller salte deraf.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK117963B (da) * 1963-07-19 1970-06-22 Ici Ltd Fremgangsmåde til fremstilling af aryloxyalkanolaminderivater eller salte deraf.
SE322506B (enrdf_load_stackoverflow) * 1964-09-10 1970-04-13 Ciba Geigy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts vol 89 (1978) abstract No. 146 611 j, Japan, Kokai 78 68, 739 *

Also Published As

Publication number Publication date
NO854518L (no) 1985-11-12
KR860700008A (ko) 1986-01-31
SE8401907L (sv) 1985-10-06
ES541850A0 (es) 1986-09-01
ZA851934B (en) 1985-11-27
EP0209520A1 (en) 1987-01-28
PT80232B (en) 1987-03-16
MY8600650A (en) 1986-12-31
DD232488A5 (de) 1986-01-29
JPS61501779A (ja) 1986-08-21
ES8609210A1 (es) 1986-09-01
SE8401907D0 (sv) 1984-04-05
PT80232A (en) 1985-05-01
GB2153828B (en) 1986-01-22
HK55586A (en) 1986-08-01
AU4231185A (en) 1985-11-01
GB8507473D0 (en) 1985-05-01
AP8500009A0 (en) 1986-10-01
GB2153828A (en) 1985-08-29
GR850840B (enrdf_load_stackoverflow) 1985-11-25
IL74611A0 (en) 1985-06-30
MA20396A1 (fr) 1985-12-31
PL252660A1 (en) 1985-11-19

Similar Documents

Publication Publication Date Title
CA1288350C (en) Controlled release dihydrocodeine composition
US6296873B1 (en) Zero-order sustained release delivery system for carbamazephine derivatives
JP5543110B2 (ja) カリウムａｔｐチャネルオープナの塩およびその使用
US20070196472A1 (en) Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
AU764742B2 (en) Dispersible compositions containing L-DOPA ethyl ester
US7273623B2 (en) Process for preparing tannate tablet, capsule or other solid dosage forms
WO1998022105A1 (fr) Preparation en comprimes
JPH08208480A (ja) 改良された溶解速度を持つネファゾドンの塩
AU2003216399A1 (en) Diphenhydramine tannate liquid and semi-solid compositions and methods of use
JPS60158197A (ja) 抗生物質およびその製法
EP0406307A1 (en) Water soluble ibuprofen compositions and methods of making them
NO873562L (no) Hurtig-absorberende og -virkende kombinasjon av sulindac eller natriumsulindac og en base.
WO1988005656A1 (en) Anhydrous, crystalline sodium salt of 5-chloro-3-(2-thenoyl)-2-oxindole-1-carboxamide
WO2003082805A1 (en) Low water-soluble venlafaxine salts
US3088871A (en) Process of stimulating the central nervous system
US6939856B2 (en) Method for preparing dexchlor tannate
US6670370B1 (en) Dextromethorphan tannate
DE69733752T2 (de) Arzneimittel enthaltend oxaprozin-natriumsalz,-kaliumsalz, oder-tris(hydroxymethyl)aminomethansalz
EP1622899A1 (en) Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
AU6971294A (en) Process for the preparation of an oral solid dosage form containing diclofenac
KR101188333B1 (ko) 안정성이 우수하고 경피제로 유용한 톨테로딘 결정성산부가염
WO1985004579A1 (en) New phenoxypropanolamine salts and pharmaceutical preparations thereof
US20050069584A1 (en) Diphenhydramine tannate solid dose compositions and methods of use
NO874040L (no) Behandlet lipidregulator.
EP0123520A1 (en) Process for preparing base salts of piroxicam deposited on a pharmaceutically-acceptable carrier

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AU DK FI HU JP KR LK NO US

AL Designated countries for regional patents

Designated state(s): AT BE CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

XX Miscellaneous:

Free format text: INT. PUBL.NO REFERRED UNDER THIS HEADING IN PCT 18/1986 SHOULD READ WO 86/01635 AND WO 85/04579